MINNEAPOLIS, MEXICO CITY (July 13, 2017) – Pharmacogenomics leader OneOme today announced it has forged a partnership with Mexico City-based Total Quality Medicine (TQM). The agreement will bring OneOme’s pharmacogenomic (PGx) testing and support services to patients in Mexico, as TQM incorporates OneOme’s RightMed PGx test into its GeneTest line of personalized medicine products.

OneOme is a Minneapolis-based leader in pharmacogenomic testing and clinical support tools that help physicians customize prescription medications based on a patient’s unique DNA. Pharmacogenomics (PGx) combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics).

TQM is a Mexico-based leader in health-related services and products. GeneTest, a division of TQM, provides a range of services and testing to personalize medical treatments through the development, design, and improvement of genetic testing.

“OneOme’s pharmacogenomic testing will complement the great advances TQM is making to improve precision medicine in Mexico,” Paul Owen, CEO of OneOme, said. “Launching this partnership means that medical providers and patients will be able to access OneOme’s product to personalize medicine and improve health.”

“OneOme’s RightMed test and supporting products will serve as an important resource to help guide providers’ prescription decisions, which may lead to more effective and safe medications for patients,” Dr. Bernard Esquivel, CEO of Total Quality Medicine, said. “TQM is glad to partner with OneOme to offer this innovative service.”

OneOme’s pharmacogenomic testing and support products are easy-to-use, intuitive and ready to be integrated into clinical practices. The RightMed pharmacogenomic test covers 22 genes and 340+ medications for more than 20 medical indications, and it can be integrated into electronic medical records (EMRs). To date, 160+ hospitals and clinics from fifteen different countries have ordered OneOme’s RightMed test.

About OneOme
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.